MedTrace Logo

Dexmedtomodine Effect on Agitated Psychotic Patients Suffer COPD

NCT06567587 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-01-13

No results posted yet for this study

Summary

Many studies approved dexmedetomodine as a drug controlled agitation for psychotic patients and also for patients on non invasive ventilation.

So we study the same effect on agitated patients who are on non invasive ventilation and also suffer of psychosis as agitation become more aggressive than usual

Conditions

  • Response of Agitated Patients to Dexmedetomidine

Interventions

DRUG

Dexmedetomidine

Effect o dexmedetomine on agitated normal and psychotic patients on BIPAP who are suffer exaggerated COPD

DEVICE

BIPAP

Put exaggerated COPD patients on non invasive ventillation

Sponsors & Collaborators

  • Laila Ahmed Abd-Elmotaleb El-Ahwal

    collaborator UNKNOWN

  • Marwa Ahmed Abogabal

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2024-11-10
Completion
2025-03-10
FDA Drug
Yes
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06567587 on ClinicalTrials.gov